SMS Pharmaceuticals reports Q1 FY25 consolidated PAT at Rs. 16.48 Cr
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Shivani Satish Wagh takes on the role of Joint Managing Director
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well
The Unit has been issued GMP Certification from ANVISA-Brazil
The new brand identity embodies Neuland's unwavering commitment to innovation, integrity, collaboration, and progress
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated